<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04281355</url>
  </required_header>
  <id_info>
    <org_study_id>EUBREAST-2 INDAX</org_study_id>
    <nct_id>NCT04281355</nct_id>
  </id_info>
  <brief_title>Individualized Locoregional Treatment of Initially Biopsy-proven Node-positive Breast Cancer After Primary Systemic Therapy</brief_title>
  <acronym>INDAX</acronym>
  <official_title>Individualized Locoregional Treatment of Initially Biopsy-proven Node-positive Breast Cancer After Primary Systemic Therapy: The EUBREAST-2 INDAX Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In clinically node-positive (cN+) breast cancer, preoperative systemic therapy (PST) is
      common. With increasing rates of complete tumour eradication, there is a need for
      de-escalation of locoregional treatment in the interest of decreased morbidity.

      In order to individually adapt postoperative therapies, axillary staging is crucial. Axillary
      lymph node dissection (ALND) comes at a high risk of arm morbidity. There is extreme
      divergence in the use of less extensive staging methods, i.e. targeted lymph node biopsy
      (TLNB), sentinel node biopsy (SNB) or both (TAD), and in the use of subsequent locoregional
      treatment, since prospective data are largely lacking.

      The main purpose of the European INDAX trial is to implement de-escalated staging and
      evaluate which regional treatment, individually adapted to the response after PST, is
      oncologically safe but least harmful.

      Population: cN+ breast cancer patients receiving PST, recruited 2021-2025. Staging by TLNB,
      TAD or SNB.

      Intervention: Negative staging (ypN0, Randomisation A, N=1433): no regional treatment.
      Positive staging (ypN+, Randomisation B, N=1513): no ALND but regional radiotherapy (rRT).

      Control: Randomisation A: rRT only. Randomisation B: ALND plus rRT.

      Outcome: Invasive disease-free survival (non-inferiority), arm morbidity and quality of life.

      Drug tests in whole-tumour organoid cultures, algorithm-based digital image analysis and gene
      expression analysis are performed to improve response prediction, facilitate tailoring of PST
      and increase eradication rates.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>iDFS</measure>
    <time_frame>5 years</time_frame>
    <description>Invasive disease-free survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2946</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Randomisation A - Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In pathologically node-negative patients on axillary staging (TAD, TLNB, SLNB) after primary systemic treatment, no regional radiotherapy is given and no axillary lymph node dissection are performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomisation B - Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In pathologically node-positive patients on axillary staging (TAD, TLNB, SLNB) after primary systemic treatment, full axillary and regional radiotherapy is given but no axillary lymph node dissection performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Omission of axillary lymph node dissection</intervention_name>
    <description>Axillary lymph node dissection will be replaced by axillary radiotherapy in Randomisation B</description>
    <arm_group_label>Randomisation A - Intervention</arm_group_label>
    <arm_group_label>Randomisation B - Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Omission of regional irradiation</intervention_name>
    <description>Regional irradiation will be omitted in the interventional arm of Randomisation A.</description>
    <arm_group_label>Randomisation A - Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with primary invasive breast cancer cT1-cT3

          -  cN1 status prior to PST

          -  Cytological or histological proof of axillary metastasis before PST

          -  Full tumour biology available before initiation of PST

          -  Oral and written consent

          -  Age â‰¥ 18 years

        Exclusion Criteria:

          -  Biopsy-confirmed regional nodal metastases outside of the ipsilateral axilla

          -  Distant metastases at diagnosis

          -  Inflammatory breast cancer

          -  Previous axillary surgery

          -  Previous radiotherapy to ipsilateral breast, chest or axilla

          -  History of prior invasive breast cancer

          -  Ongoing pregnancy or breast-feeding

          -  Bilateral invasive breast cancer

          -  Medical contraindication for radiotherapy or inability to receive recommended
             radiotherapy

          -  Medical contraindication for adjuvant endocrine treatment, if indicated

          -  Inability to absorb or understand the meaning of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jana M de Boniface, MD PhD</last_name>
    <phone>+46858701000</phone>
    <email>jana.de-boniface@ki.se</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Jana de Boniface</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

